Infliximab interstitial pneumonitis

Respiratory Interstitial pneumonitis associated with infliximab has been reported in a patient with rheumatoid arthritis [44 ]. 

Taki H, Kawagishi Y, Shinoda K, Hounoki H, Ogawa R, Sugiyama E, Tobe K. Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment. Rheumatol Int 2009 30(2) 275-6. 

Systemic and cutaneous reactions have been reported following administration of infliximab. These include anaphylaxis, serum sickness, maculopapular rashes, urticaria, psoriasis, flare-up of atopic dermatitis, and leukocytoclastic vascuhtis. The overall incidence of infusion reactions in one study was 6.1 %. Mild, moderate, and severe reactions occurred in 3.1, 1.2, and 1 % of infliximab infusions, respectively. Patients with lymphocyte counts greater than 50 XIQP/L experienced a severe cytokine release syndrome shown by peaks in release of TNF and lL-6 90 min after infusion with rituximab. A number of post-infusion hypersensitivity or hypersensitivity-like reactions occur to rituximab. These reactions include serum sickness, vasculitis, various cutaneous manifestations, interstitial pneumonitis, and acute respiratory distress syndrome. 

Respiratory Exacerbations of fibrosing alveolitis, interstitial pneumonitis, and bron-chospasm in patients using infliximab have been described [114", 115" ]. 

Chatterjee S. Severe interstitial pneumonitis associated with infliximab therapy. Scand J Rheumatol 2004 33 276-277. 

---

See also in sourсe #XX -- [ ]

---